Characterization of Programmed Cell Death-1 Ligand(PD-L1) Expression in Circulating Tumor Cells (CTCs) of Lung Cancer. ACCR IASLC 2016
Programmed Death-1 Ligand (PD-L1) Expression on Circulating CD45(-) Cells is an Independent Prognostic Factor for Overall Survival in Patients with Lung Cancer ASCO 2016
Circulating Tumor Cell (CTC) Detection and 5T4 Characterization in Breast, Ovarian,and Lung Cancer Patients on Active Therapy. AACR 2015
The expression of fetal oncogene 5T4 in CTCs obtained from NSCLC patients is discordant with the expression measured in the primary tumor. AACR 2015
Characterization of ALK fusions in circulating tumor cells (CTCs) of NSCLC. AACR 2014
Characterization of molecular targets of therapy in Non-Small Cell Lung Cancer (NSCLC) utilizing a liquid biopsy. EORTC 2014
Characterization of PD-L1 expression in Circulating Tumor Cells (CTCs) of Non-Small Cell Lung Cancer (NSCLC) patients. EORTC 2014
Return to Posters
Return to Technical Resources
Return to Analysis by Cancer Indication
